MetaCap

Unicycive Therapeutics Inc. (UNCY)

NASDAQ: UNCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.35-0.18 (-5.10%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

UNCY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$97.77M
EPS (TTM)
-$1.64
52-week range
3.33 – 8.74
Day range
3.35 – 3.62
Volume / Avg
1.36M / 963.80K
Beta
—

52-week range

$3.33$8.74

UNCY stock today

Shares of Unicycive Therapeutics (UNCY) finished lower on Nov 20 at $3.35, a drop of 5.10% or $0.18 per share, versus the S&P 500's 3.70% decline. Shares are 61.7% below their 52-week high of $8.74, set on May 14, 2026 and 0.6% above the 52-week low of $3.33, near the bottom of the past year's range. UNCY is down 41.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 38.0%.

Unicycive Therapeutics has posted a net loss over the last twelve months (EPS of -$1.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Unicycive Therapeutics

Company profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Shalabh K. Gupta M.D., MPA
Headquarters
Mountain View, CA
Employees
21
IPO year
2021

Financial highlights

Full financials

Unicycive Therapeutics reported a net loss of $26.6 million, compared with a loss of $36.7 million a year earlier. Diluted earnings per share came in at -$1.67.

Unicycive Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$675.00K$951.00K—
Growth——-29.02%——
Net income$-26.55M$-36.73M$-30.54M$-18.06M$-10.02M
EPS (diluted)$-1.67$-5.65$-1.28$-1.20$-0.86

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$26.30+685.07%

  • Strong buy 2
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $13.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.25 vs $-0.33
Surprise
+24.24%

UNCY news

All UNCY news

Unicycive Therapeutics peers

Health Care sector
UNCY peer companies
CompanyPrice% ChgMarket capCompare
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs UNCY
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs UNCY
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs UNCY
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs UNCY
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs UNCY
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs UNCY
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs UNCY
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs UNCY

Indexes, lists and sector

Unicycive Therapeutics stock FAQ

What is Unicycive Therapeutics's stock price today?

UNCY last traded at $3.35 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.

Does Unicycive Therapeutics pay a dividend?

No. Unicycive Therapeutics does not currently pay a regular cash dividend.

Who is Unicycive Therapeutics's CEO?

Dr. Shalabh K. Gupta M.D., MPA is the chief executive officer of Unicycive Therapeutics Inc., which has about 21 employees.

Has UNCY ever split its stock?

Yes. The most recent UNCY stock split was a 1-for-10 split on Jun 20, 2025.

What is the UNCY 52-week high?

The 52-week high for UNCY is $8.74 and the 52-week low is $3.33. The stock is currently 61.7% below its high.

Compare UNCY